NASDAQ:AGTCApplied Genetic Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Applied Genetic Technologies Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.96 +0.18 (+3.77 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$4.80Now: $4.96▼$5.0850-Day Range$3.63MA: $4.19▼$5.0352-Week Range$2.29Now: $4.96▼$10.42Volume11,632 shsAverage Volume270,035 shsMarket Capitalization$127.77 millionP/E RatioN/ADividend YieldN/ABeta2.73 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. The company also has initiated one preclinical program in otology and three preclinical programs in targeting central nervous system disorders, including one in adrenoleukodystrophy. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited and University of Florida; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingApplied Genetic Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.50, Applied Genetic Technologies has a potential upside of 232.7% from its current price of $4.96.Amount of Analyst CoverageApplied Genetic Technologies has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesApplied Genetic Technologies has received 401 “outperform” votes. (Add your “outperform” vote.)Underperform VotesApplied Genetic Technologies has received 264 “underperform” votes. (Add your “underperform” vote.)Community SentimentApplied Genetic Technologies has received 60.30% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote “Outperform” if you believe AGTC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldApplied Genetic Technologies does not currently pay a dividend.Dividend GrowthApplied Genetic Technologies does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Applied Genetic Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.10% of the stock of Applied Genetic Technologies is held by insiders.Percentage Held by Institutions58.25% of the stock of Applied Genetic Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Applied Genetic Technologies are expected to grow in the coming year, from ($2.05) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Applied Genetic Technologies is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Applied Genetic Technologies is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioApplied Genetic Technologies has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AGTC Previous Symbol CUSIPN/A CIK1273636 Webwww.agtc.com Phone386-462-2204Debt Debt-to-Equity Ratio0.05 Current Ratio6.46 Quick Ratio6.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$41.69 million Price / Sales3.06 Cash FlowN/A Price / Cash FlowN/A Book Value$4.33 per share Price / Book1.15Profitability EPS (Most Recent Fiscal Year)($0.11) Net Income$-2,010,000.00 Net MarginsN/A Return on Equity-57.49% Return on Assets-46.02%Miscellaneous Employees85 Outstanding Shares25,760,000Market Cap$127.77 million Next Earnings Date9/24/2020 (Estimated) OptionableOptionable NASDAQ:AGTC Rates by TradingView Receive AGTC News and Ratings via Email Sign-up to receive the latest news and ratings for AGTC and its competitors with MarketBeat's FREE daily newsletter. Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions How has Applied Genetic Technologies' stock been impacted by COVID-19 (Coronavirus)? Applied Genetic Technologies' stock was trading at $3.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AGTC stock has increased by 29.2% and is now trading at $4.96. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Applied Genetic Technologies? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Applied Genetic Technologies. When is Applied Genetic Technologies' next earnings date? Applied Genetic Technologies is scheduled to release its next quarterly earnings announcement on Thursday, September 24th 2020. View our earnings forecast for Applied Genetic Technologies. How were Applied Genetic Technologies' earnings last quarter? Applied Genetic Technologies Corp (NASDAQ:AGTC) posted its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. View Applied Genetic Technologies' earnings history. What price target have analysts set for AGTC? 6 analysts have issued 1 year target prices for Applied Genetic Technologies' shares. Their forecasts range from $10.00 to $25.00. On average, they anticipate Applied Genetic Technologies' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 232.7% from the stock's current price. View analysts' price targets for Applied Genetic Technologies. Has Applied Genetic Technologies been receiving favorable news coverage? News articles about AGTC stock have trended positive on Tuesday, InfoTrie Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Applied Genetic Technologies earned a daily sentiment score of 2.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutApplied Genetic Technologies. Who are some of Applied Genetic Technologies' key competitors? Some companies that are related to Applied Genetic Technologies include Innate Pharma (IPHYF), Harpoon Therapeutics (HARP), Voyager Therapeutics (VYGR), PDL BioPharma (PDLI), Precision BioSciences (DTIL), Verona Pharma (TARA), Eiger Biopharmaceuticals (EIGR), Cellular Biomedicine Group (CBMG), CASI Pharmaceuticals (CASI), ADMA Biologics (ADMA), Tcr2 Therapeutics (TCRR), Gritstone Oncology (GRTS), Sutro Biopharma (STRO), Brainstorm Cell Therapeutics (BCLI) and Cabaletta Bio (CABA). View all competitors. What other stocks do shareholders of Applied Genetic Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Applied Genetic Technologies investors own include Micron Technology (MU), SCYNEXIS (SCYX), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Galmed Pharmaceuticals (GLMD), Crispr Therapeutics (CRSP), Allena Pharmaceuticals (ALNA), Fortress Biotech (FBIO) and Inovio Pharmaceuticals (INO). Who are Applied Genetic Technologies' key executives? Applied Genetic Technologies' management team includes the following people: Ms. Susan B. Washer, Pres, CEO & Director (Age 59, Pay $777.27k)Dr. Mark S. Shearman, Chief Scientific Officer (Age 60, Pay $538.93k)Dr. Matthew Feinsod, Exec. VP of Global Strategy & Devel. (Age 49, Pay $711.2k)Dr. Nicholas Muzyczka, Co-FounderDr. Barry J. Byrne, Co-Founder What is Applied Genetic Technologies' stock symbol? Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC." Who are Applied Genetic Technologies' major shareholders? Applied Genetic Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include DAFNA Capital Management LLC (6.37%), Sofinnova Investments Inc. (5.83%), Acadian Asset Management LLC (4.79%), Stonepine Capital Management LLC (3.22%), Ikarian Capital LLC (3.00%) and Portolan Capital Management LLC (2.61%). Company insiders that own Applied Genetic Technologies stock include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan and William Aliski. View institutional ownership trends for Applied Genetic Technologies. Which major investors are selling Applied Genetic Technologies stock? AGTC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View insider buying and selling activity for Applied Genetic Technologies. Which major investors are buying Applied Genetic Technologies stock? AGTC stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., DAFNA Capital Management LLC, Stonepine Capital Management LLC, Portolan Capital Management LLC, Ghost Tree Capital LLC, Ikarian Capital LLC, Russell Investments Group Ltd., and Assenagon Asset Management S.A.. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Patrick Johan Hendrik Krol, Susan B Washer, William A Sullivan, and William Aliski. View insider buying and selling activity for Applied Genetic Technologies. How do I buy shares of Applied Genetic Technologies? Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Applied Genetic Technologies' stock price today? One share of AGTC stock can currently be purchased for approximately $4.96. How big of a company is Applied Genetic Technologies? Applied Genetic Technologies has a market capitalization of $127.77 million and generates $41.69 million in revenue each year. The biotechnology company earns $-2,010,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Applied Genetic Technologies employs 85 workers across the globe. What is Applied Genetic Technologies' official website? The official website for Applied Genetic Technologies is www.agtc.com. How can I contact Applied Genetic Technologies? Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204. This page was last updated on 6/2/2020 by MarketBeat.com Staff
